Abstract:Schistosomiasis, also known as bilharzia or snail fever, is a tropical parasitic disease resulting from flatworms of the Schistosoma genus. This often overlooked disease has significant impacts in affected regions, causing enduring morbidity, hindering child development, reducing productivity, and creating economic burdens. Praziquantel (PZQ) is currently the only treatment option for schistosomiasis. Given the potential rise of drug resistance and the limited treatment choices available, there is a need to develop more effective inhibitors for this neglected tropical disease (NTD). In view of this, quantitative structure-activity relationship studies (QSAR), molecular docking, molecular dynamics simulations, drug-likeness, and ADMET predictions were applied to 31 inhibitors of Schistosoma mansoni Dihydroorotate dehydrogenase (SmDHODH). The designed QSAR model demonstrated robust statistical parameters including an R 2 of 0.911, R 2 adj of 0.890, Q 2 cv of 0.686, R 2 pred of 0.807, and cR 2 p of 0.825, confirming its robustness. Compound 26 , identified as the most active derivative, emerged as a lead candidate for new potential inhibitors through ligand-based drug design. Subsequently, 12 novel compounds ( 26A - 26L ) were designed with enhanced inhibition activity and binding affinity. Molecular docking studies revealed strong and stable interactions, including hydrogen bonding and hydrophobic interactions, between the designed compounds and the target receptor. Molecular dynamics simulations over 100 nanoseconds and MM-PBSA free binding energy (ΔG bind ) calculations validated the stability of the two best-designed molecules ( 26A and 26L ). Furthermore, drug-likeness and ADMET prediction analyses affirmed the potential of these designed compounds, suggesting their promise as innovative agents for treating schistosomiasis. In an innovative effort to combat schistosomiasis, we have employed a computational drug innovation approach to design a potential treatment options. Schistosomiasis, a parasitic disease affecting millions worldwide, has been a persistent global health challenge. The study, nestled within the broader realm of life sciences, sought to identify a more effective drug using computational methods that analyze highly effective derivatives targeting SmDHODH. This pioneering approach not only accelerates the drug discovery process but also offers a promising avenue for developing targeted treatments. By harnessing computational power, we systematically explored chemical databases to pinpoint compounds with the potential to combat schistosomiasis. The findings hold significant implications for both scientists and non-scientists, as they represent a step forward in addressing a major public health concern. For scientists, this work exemplifies the integration of in silico techniques in drug development, while non-scientists can appreciate the tangible impact on improving global health and the well-being of communities affected by schistosomiasis. This research underscores the power of interdisciplinary efforts in advancing our ability to tackle complex health challenges.

Crystallographic approach to fragment-based hit discovery against Schistosoma mansoni purine nucleoside phosphorylase

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?

Fragment library screening by X-ray crystallography and binding site analysis on thioredoxin glutathione reductase of Schistosoma mansoni

Integration and use of Schistosoma mansoni genomic data towards the identification of candidate therapeutic targets

Computer-aided discovery of novel SmDHODH inhibitors for schistosomiasis therapy: Ligand-based drug design, molecular docking, molecular dynamic simulations, drug-likeness, and ADMET studies

High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni

Aldose Reductase from Schistosoma Japonicum: Crystallization and Structure-Based Inhibitor Screening for Discovering Antischistosomal Lead Compounds.

Artificial intelligence-guided approach for efficient virtual screening of hits against Schistosoma mansoni

QSAR-Driven Design and Discovery of Novel Compounds With Antiplasmodial and Transmission Blocking Activities

Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S . mansoni larval and adult worm stages

Computational Insights into Natural Antischistosomal Metabolites as SmHDAC8 Inhibitors: Molecular Docking, ADMET Profiling, and Molecular Dynamics Simulation

Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infection

Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds

Identification of Inhibitors of the Schistosoma mansoni VKR2 Kinase Domain

Development of subunit selective proteasome substrates for

Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni

Extensive transmission and variation in a functional receptor for praziquantel resistance in endemic Schistosoma mansoni

In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment

Unveiling Potential Repurposed Drug Candidates for Plasmodium falciparum through In Silico Evaluation: A Synergy of Structure-based Approaches, Structure Prediction, and Molecular Dynamics Simulations